Abstract
Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer-related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the patterns of gene expression. The molecular events in prostate cancer are beginning to be understood, including altered expression of tumor suppressor genes, pro- and anti-apoptotic genes, and oncogenes associated with the progression of the disease, and specific genes that are expressed predominantly or exclusively in prostate cells, prostate cancer cells, and prostate metastasis cells. These latter genes on the level of DNA, RNA and protein products are the targets of several new approaches to prostate cancer therapy and are the focus of this review.
Keywords: prostate, cancer, peptidase, prostate specific antigen (psa), prodrug, gene therapy, androgen, antisense
Current Pharmaceutical Design
Title: Drug-Targeting Strategies for Prostate Cancer
Volume: 9 Issue: 6
Author(s): Gil Ast
Affiliation:
Keywords: prostate, cancer, peptidase, prostate specific antigen (psa), prodrug, gene therapy, androgen, antisense
Abstract: Prostate cancer is the most frequently diagnosed cancer in North American men and accounts for 10% of cancer-related deaths in men. Despite advances in early detection and aggressive treatment of early disease, the overall mortality rate has not appear to have fallen, indicating that the current therapies are not beneficial for life expectancy and new strategies are required. Prostate cancer is a dynamic evolving process that develops in distinct steps, with each step liable to additional genetic hits that change the cancer cell phenotype and alter the patterns of gene expression. The molecular events in prostate cancer are beginning to be understood, including altered expression of tumor suppressor genes, pro- and anti-apoptotic genes, and oncogenes associated with the progression of the disease, and specific genes that are expressed predominantly or exclusively in prostate cells, prostate cancer cells, and prostate metastasis cells. These latter genes on the level of DNA, RNA and protein products are the targets of several new approaches to prostate cancer therapy and are the focus of this review.
Export Options
About this article
Cite this article as:
Ast Gil, Drug-Targeting Strategies for Prostate Cancer, Current Pharmaceutical Design 2003; 9 (6) . https://dx.doi.org/10.2174/1381612033391603
DOI https://dx.doi.org/10.2174/1381612033391603 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Current Pharmaceutical Design Recapitulation of Cancer Nanotherapeutics
Current Nanomedicine Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine Effects of Aging on Thyroidal Function and Proliferation
Current Aging Science Cytotoxicity of Hydrazones of Morpholine Bearing Mannich Bases Towards Huh7 and T47D Cell Lines and Their Effects on Mitochondrial Respiration
Letters in Drug Design & Discovery Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery High Throughput Screening for Colorectal Cancer Specific Compounds
Combinatorial Chemistry & High Throughput Screening Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Biomarkers Natural Products as a Source for Antileishmanial and Antitrypanosomal Agents
Combinatorial Chemistry & High Throughput Screening Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective
Infectious Disorders - Drug Targets